Dashboard
Manage Tickers

XOMA XOMA Royalty Corp

Nasdaq xoma.com


$ 32.97 nm (nm)    

Friday, 31-Oct-2025 15:59:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.08 nm (nm)
DIA $ 475.80 $ 0.66 (0.14 %)
SPY $ 682.01 nm (nm)
TLT $ 90.33 nm (nm)
GLD $ 368.25 $ -2.01 (-0.54 %)
$ 33.22
$ 32.77
$ 32.12 x 194
$ 37.50 x 1
$ 32.59 - $ 33.90
$ 18.35 - $ 39.92
35,653
na
401.55M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-10-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 03-10-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-06-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-07-2018 12-31-2017 10-K
32 11-06-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 03-09-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Mural Oncology Shareholders Approve Takeov...
10/24/2025 20:27:29

Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously a...

Core News & Articles
XOMA and LAVA Therapeutics Announce Amendm...
10/17/2025 15:48:30

- Amendment includes finalized cash amount and updated CVR terms for tender offer- LAVA announces new date for extraordinary ge...

xoma-royalty-may-offer--sell-shares-of-common-stock-from-time-to-time-of-up-to-75m
XOMA Royalty May Offer & Sell Shares Of Co...
10/03/2025 21:51:58

-SEC Filing

Core News & Articles
XOMA Royalty And LAVA Therapeutics Announc...
10/02/2025 20:47:45

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (&...

Core News & Articles
ESSA Pharma Amends Agreement With XenoTher...
09/24/2025 10:07:16

Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.1...

Core News & Articles
Reported Earlier, Mural Oncology Publishes...
09/24/2025 06:35:13

Core News & Articles
Mural Oncology To be Acquired By Xoma Roya...
08/20/2025 12:31:28

xoma-q2-2025-eps-044-may-not-be-comparable-to-020-estimate-sales-13129m-beat-9700m-estimate
XOMA Q2 2025 EPS $0.44 May Not Be Comparab...
08/13/2025 11:35:44

Core News & Articles
XOMA Royalty To Acquire Lava Therapeutics ...
08/04/2025 11:34:03

Core News & Articles
Xoma Royalty Agrees To Acquire HilleVax $1...
08/04/2025 11:03:38

Under the terms of the Merger Agreement, HilleVax stockholders will receive $1.95 in cash per share of HilleVax common stock at...

xoma-royalty-corporation-is-acting-as-the-structuring-agent-and-will-provide-financing-to-xeno-for-essa-pharma-transaction
XOMA Royalty Corporation Is Acting As The ...
07/14/2025 12:07:40

xoma-royalty-stock-a-deep-dive-into-analyst-perspectives-4-ratings
XOMA Royalty Stock: A Deep Dive Into Analy...
05/28/2025 12:01:25

hc-wainwright--co-reiterates-buy-on-xoma-royalty-maintains-104-price-target
HC Wainwright & Co. Reiterates Buy on XOMA...
05/28/2025 10:36:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:XOMA) with a Buy and maintains $104 price t...

xoma-royalty-purchases-future-mezagitamab-royalty-and-milestone-interests-held-by-bioinvent-for-20m-at-closing-with-total-transaction-of-up-to-30m
XOMA Royalty Purchases Future Mezagitamab ...
05/27/2025 12:13:54

benchmark-initiates-coverage-on-xoma-royalty-with-buy-rating-announces-price-target-of-35
Benchmark Initiates Coverage On XOMA Royal...
04/17/2025 12:41:23

Benchmark analyst Robert Wasserman initiates coverage on XOMA Royalty (NASDAQ:XOMA) with a Buy rating and announces Price Ta...

the-analyst-verdict-xoma-royalty-in-the-eyes-of-4-experts
The Analyst Verdict: XOMA Royalty In The E...
03/28/2025 13:00:46

hc-wainwright--co-reiterates-buy-on-xoma-royalty-maintains-104-price-target
HC Wainwright & Co. Reiterates Buy on XOMA...
03/28/2025 11:38:47

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:XOMA) with a Buy and maintains $104 price t...

hc-wainwright--co-reiterates-buy-on-xoma-royalty-maintains-104-price-target
HC Wainwright & Co. Reiterates Buy on XOMA...
03/19/2025 10:21:16

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:XOMA) with a Buy and maintains $104 price t...

xoma-q4-2024-gaap-eps-045-misses-030-estimate-sales-871m-miss-875m-estimate
XOMA Q4 2024 GAAP EPS $(0.45) Misses $(0.3...
03/17/2025 21:51:21

XOMA (NASDAQ:XOMA) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.30) by 50 ...

Core News & Articles
Ligand Pharmaceuticals Closed A Royalty Fi...
02/25/2025 12:17:56

Ligand originated, structured, and invested $50 million and led a syndicate of co-investors who invested $25 million in exchang...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION